Scopus
YÖKSİS Eşleşti
The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data
Infectious Diseases and Clinical Microbiology · Eylül 2024
YÖKSİS Kayıtları
The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data
Infectious Diseases and Clinical Microbiology · 2024 esci
PROFESÖR NAZLIM AKTUĞ DEMİR →
The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data
Infectious Diseases and Clinical Microbiology · 2024 TÜBİTAK ULAKBİM TR DİZİN
PROFESÖR ŞUA SÜMER →
Makale Bilgileri
DergiInfectious Diseases and Clinical Microbiology
Yayın TarihiEylül 2024
Cilt / Sayfa6 · 216-224
Scopus ID2-s2.0-85211167386
Özet
Objective: This study aimed to demonstrate the real-life efficacy and safety of glecaprevir / pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients. Materials and Methods: The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-naïve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment Results: Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events. Conclusion: Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics.
Yazarlar (26)
1
Yunus Gürbüz
ORCID: 0000-0002-8772-0769
2
Aysel Kocagül-çelikbaş
ORCID: 0000-0002-7448-5210
3
Nefise Oztoprak
4
Bilgehan Aygen
ORCID: 0000-0002-7598-6578
5
Ayse Batirel
6
Arif Doğan Habiloğlu
ORCID: 0000-0001-8122-8768
7
Nazlım Aktuğ Demir
8
Sabahat Çeken
ORCID: 0000-0002-3679-0978
9
Neşe Demirtürk
ORCID: 0000-0002-6186-2494
10
Mehmet Reşat Ceylan
ORCID: 0000-0001-8063-4836
11
Şengül Üçer
ORCID: 0000-0002-1764-3198
12
Faruk Karakeçili
ORCID: 0000-0002-7368-7187
13
Sevil Alkan
ORCID: 0000-0003-1944-2477
14
Nevin İnce
ORCID: 0000-0002-0129-4536
15
Anıl Akça
ORCID: 0000-0001-5029-9838
16
Veli Günay
ORCID: 0000-0001-9151-0636
17
Duru Mustanoğlu-özatağ
ORCID: 0000-0002-0005-192X
18
Güle Çınar
ORCID: 0000-0002-7635-8848
19
Sami Kınıklı
ORCID: 0000-0002-9661-7851
20
Orhan Yıldız
ORCID: 0000-0001-6019-0430
21
Petek Şarlak-Konya
ORCID: 0000-0001-5055-1220
22
Şua Sümer
23
Dilek Yekenkurul
ORCID: 0000-0002-4456-7485
24
Mehmet Çelik
ORCID: 0000-0002-0583-929X
25
Umut Devrim Binay
ORCID: 0000-0003-3841-9109
26
Zahide Aşık-Otman
ORCID: 0000-0002-1729-2922
Anahtar Kelimeler
chronic hepatitis C
COVID-19
glecaprevir
multicenter study
pibrentasvir
Kurumlar
Afyonkarahisar Health Sciences University
Afyonkarahisar Turkey
Ankara Numune Education and Research Hospital
Ankara Turkey
Ankara Üniversitesi
Ankara Turkey
Antalya Training and Research Hospital
Antalya Turkey
Çanakkale Onsekiz Mart Üniversitesi
Canakkale Turkey
Düzce Üniversitesi
Duzce Turkey
Erciyes University, Faculty of Medicine
Kayseri Turkey
Erzincan Binali Yıldırım Üniversitesi
Erzincan Turkey
Harran University, Faculty of Medicine
Sanliurfa Turkey
Hitit University
Corum Turkey
Kartal Dr. Lütfi Kırdar City Hospital
Istanbul Türkiye
Kütahya Sağlık Bilimleri Üniversitesi
Kutahya Turkey
Selçuk Üniversitesi
Selçuklu Turkey
T.C. Sağlık Bakanlığı,
Ankara Turkey
University of Health Sciences
Istanbul Turkey